Macter International Limited has reported a 9 percent increase in net profit for the first half of fiscal year 2026, reflecting strong revenue growth and improved operational efficiency despite a challenging economic environment.
Read More: BMW Pakistan Announces Major Ramadan Discounts on Electric Vehicles
The pharmaceutical manufacturer posted a net profit of Rs 427.2 million for the six months ended December 31, 2025, compared to Rs 392 million in the corresponding period last year. Earnings per share (EPS) rose to Rs 9.32, underlining the company’s steady value creation for shareholders.
Revenue from contracts with customers surged 24.2 percent year-on-year to Rs 6.11 billion, driven by sustained demand across domestic and export markets. The strong top-line performance highlights Macter International’s expanding market presence and diversified product portfolio within Pakistan’s growing pharmaceutical sector.
Gross profit increased by 33.7 percent to Rs 2.94 billion, with gross margins improving to 48.2 percent from 44.8 percent a year earlier. The margin expansion reflects effective cost controls, operational efficiencies and improved pricing strategies, strengthening the company’s core profitability.
Operating profit climbed 33.2 percent to Rs 831.9 million, demonstrating the resilience of the company’s business model. However, higher income tax expenses during the period moderated overall bottom-line growth, resulting in a net profit margin of approximately 7 percent.
Industry analysts view the results as a positive signal for Pakistan’s pharmaceutical sector, which continues to navigate currency volatility, regulatory pressures and rising input costs. Macter International’s performance in the first half of FY2026 suggests the company remains well-positioned to sustain growth momentum in the coming quarters.
With strong revenue expansion, improved margins and disciplined financial management, Macter International has reinforced its standing as a key player in Pakistan’s pharmaceutical industry.
